Summit Therapeutics PLC Sponsored ADR Stock

$12.27

1.84% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$12.27

+10.92 808.89% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.23 1.84%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$8.89b
Enterprise Value	$8.67b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	45.56
Revenue growth (TTM) Revenue growth	-100.00%
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-144.53m
Free Cash Flow (TTM) Free Cash Flow	$-96.67m
Cash position	$325.79m
EPS (TTM) EPS	$-0.23
P/E forward	negative
Short interest	16.30%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.25 1.25	- -
Gross Profit	-1.25 -1.25	- -
- Selling and Administrative Expenses	40 40	79% 79% -
- Research and Development Expense	102 102	146% 146% -
EBITDA	-143 -143	118% 118% -
- Depreciation and Amortization	1.25 1.25	42% 42% -
EBIT (Operating Income) EBIT	-145 -145	113% 113% -
Net Profit	-162 -162	73% 73% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Neutral

Business Wire

●

one day ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 102,000 shares of common stock. Awards were made to five new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Compan...

Neutral

PRNewsWire

●

27 days ago

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC HONG KONG , Aug. 11, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced two upcoming oral presentations of ivonescimab (PD-1/VE...

Neutral

Seeking Alpha

●

29 days ago

Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q2 2024 Results Conference Call August 6, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and Chief Executive Officer Maky Zanganeh - Chief Executive Officer, President Manmeet Soni - Chief Operating Officer Allen Yang - Chief Medical Officer Conference Call Participants Dara Azar - Stifel Yiga...

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	105
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now